Division of Pulmonary, Critical Care & Sleep Medicine

Mark M. Fuster, M.D.

Associate Professor In Residence

VA Medical Center



  1. Lung Cancer
  2. Radiation tumor biology and lung injury
  3. Thromboembolic pathophysiology



  1. Mechanisms of tumor neovacularization
  2. Roles of tumor glycoscylation in metastasis
  3. Role of proteoglycans in tumor lymphatic progression
  4. Radiation tumor biology
  5. Thromboembolism in cancer



  1. Fuster MM, DeTraversay J, and Ornitz EM. (1994) Maturation of the fast component of vestibular nystagmus during childhood and young adulthood. Acta Otolaryngol (Stockh). 114: 239-44.
  2. Belting M, Borsig L, Fuster MM, Brown J, Persson L, Fransson LA, and Esko JD. (2001) Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci U S A. 99:371-376.
  3. Brown JR, Fuster MM, and Esko JD. (2001) Glycoside decoys of glycosylation. Trends in Gycoscience and Glycotechnology. 13:335-43.
  4. Brown JR, Fuster MM, and Esko JD. (2003) Expression patterns of alpha 2,3-sialyltransferases and alpha 1,3-fucosyltransferases determine the mode of sialyl Lewis X inhibition by disaccharide decoys. J Biol Chem. 278:23352-23359.
  5. Fuster MM, Brown JR, Wang L, and Esko JD. (2003) A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res. 63:2775-2781.
  6. Wang L, Fuster MM, Sriramarao P, Varki N, and Esko JD. (2005) Deficiency of heparan sulfate N-deacetylase/ N-sulfotransferase-1 in endothelium impairs selectin and chemokine mediated neutrophil trafficking. Nat Immunol. 6:902-910.
  7. Fuster MM and Esko JD. The sweet and sour of cancer: Novel therapeutic avenues. (2005) Nat Rev Cancer. 5:526-542.
  8. Brown JI, Fuster MM, Li R, Glass CA, and Esko JD. (2006) A disaccharide inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clin Cancer Res. 12:2894-2901.
  9. Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PHA, Radek KA, Schuksz M, Bishop JR, Gallo RL, Sriramarao P, and Esko JD. (2007) Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol. 177:539-549.
  10. Garmy-Susini B, Makale M, Fuster MM, Varner JA. (2007) Methods to study lymphatic vessel integrins. Methods Enzymol. 426:415-438.
  11. Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, Glass CA, Wang L, Elson-Shwab L, Tor Y, and Esko JD. (2007) Surfen – A small molecule antagonist of heparan sulfate.  Proc Natl Acad Sci USA 2008;105:13075-80.
  12. Zuberi R, Ge XN, Jiang S, Bahaie N, Kang BN, Hosseinkhani R, Frenzel EM, Fuster MM, Esko JD, Rao S, and Sriramarao P. Deficiency of endothelial heparan sulfates attenuates allergic airway inflammation. J Immunol 2009, 183:3971-9
  13. Sandhu AP, Messer M, Fuster MM, Ahmad E, Pu M, Bazhenova L, Nobiensky P, Rose M, and Seagren S. Definitive radiation therapy for stage I non-small cell carcinoma: institutional experience with contemporary conformal planning. Clin Lung Cancer 2009, 10:433-7
  14. Yin X, Johns SC, Lawrence R, Bishop JR, Reddi K, Schuksz M, and Fuster MM. VEGF-C signaling and pathologic lymphangiogenesis depends on heparan sulfate. 2009 (Submitted Manuscript)


Board Certified:

  • Internal Medicine
  • Pulmonary Medicine
  • Critical Care Medicine

Dr. Fuster's Lab :


VA Medical Center

For more information write to mfuster@ucsd.edu